Feedback / Questions
pro-doxorubicin (AVA6000) - Avacta
https://www.globenewswire.com/news-release/2023/12/13/2795421/0/en/ALS-6000-101-Phase-1a-Three-Weekly-Dose-Escalation-Safety-Study-Data.html
Dec 13, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next